Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MORNASDAQ:PTGXNASDAQ:QURENASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APTGXProtagonist Therapeutics$44.49-0.8%$45.45$24.22▼$60.60$2.73B2.3855,688 shs634,255 shsQUREuniQure$14.18-0.6%$11.92$3.73▼$19.18$766.81M0.421.77 million shs646,241 shsSRRKScholar Rock$32.81-4.6%$32.77$6.76▼$46.98$3.11B0.561.24 million shs694,304 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMORMorphoSys0.00%0.00%0.00%0.00%+5.04%PTGXProtagonist Therapeutics-2.84%-3.09%-12.14%+19.00%+74.51%QUREuniQure-0.90%+9.69%-0.70%-9.00%+212.72%SRRKScholar Rock+5.50%+11.97%+3.31%-21.42%+144.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics3.796 of 5 stars4.53.00.00.02.92.51.3QUREuniQure2.3269 of 5 stars3.42.00.00.02.42.50.6SRRKScholar Rock4.0815 of 5 stars3.50.00.04.44.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMORMorphoSys 0.00N/AN/AN/APTGXProtagonist Therapeutics 3.00Buy$65.4447.10% UpsideQUREuniQure 2.82Moderate Buy$38.80173.62% UpsideSRRKScholar Rock 3.00Buy$42.6730.04% UpsideCurrent Analyst Ratings BreakdownLatest QURE, MOR, SRRK, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/1/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$27.00 ➝ $38.003/28/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/11/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.003/11/2025PTGXProtagonist TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $76.003/11/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$62.00 ➝ $72.003/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $54.003/4/2025PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$53.00 ➝ $57.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PTGXProtagonist Therapeutics$434.43M6.29N/AN/A$5.84 per share7.62QUREuniQure$27.12M28.28N/AN/A$4.34 per share3.27SRRKScholar Rock$33.19M93.77N/AN/A$3.12 per share10.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APTGXProtagonist Therapeutics-$78.96M$4.2016.73N/AN/A52.76%34.68%30.98%5/6/2025 (Estimated)QUREuniQure-$308.48M-$4.93N/AN/AN/A-837.80%-188.82%-32.17%5/6/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/6/2025 (Estimated)Latest QURE, MOR, SRRK, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50N/AN/AN/A$30.44 millionN/A5/6/2025Q1 2025QUREuniQure-$1.07N/AN/AN/AN/AN/A5/6/2025Q1 2025SRRKScholar Rock-$0.63N/AN/AN/AN/AN/A2/21/2025Q4 2024PTGXProtagonist Therapeutics-$0.09$1.98+$2.07$1.98$56.65 million$170.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMORMorphoSysN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMORMorphoSys4.981.381.38PTGXProtagonist TherapeuticsN/A10.6910.70QUREuniQure0.926.516.51SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMORMorphoSys18.38%PTGXProtagonist Therapeutics98.63%QUREuniQure78.83%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipMORMorphoSys0.05%PTGXProtagonist Therapeutics5.40%QUREuniQure4.74%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePTGXProtagonist Therapeutics12061.38 million56.38 millionOptionableQUREuniQure50054.08 million46.43 millionOptionableSRRKScholar Rock14094.86 million75.64 millionOptionableQURE, MOR, SRRK, and PTGX HeadlinesRecent News About These CompaniesScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Hood River Capital Management LLCApril 25 at 7:19 AM | marketbeat.comHarvest Investment Services LLC Buys Shares of 9,635 Scholar Rock Holding Co. (NASDAQ:SRRK)April 25 at 6:05 AM | marketbeat.comPiper Sandler Remains a Buy on Scholar Rock Holding (SRRK)April 24 at 8:29 PM | markets.businessinsider.comSilverarc Capital Management LLC Purchases Shares of 183,243 Scholar Rock Holding Co. (NASDAQ:SRRK)April 24 at 7:35 AM | marketbeat.comCapital World Investors Takes $31.20 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)April 24 at 5:23 AM | marketbeat.comWhy Scholar Rock Holding Stock Topped the Market TodayApril 23 at 7:01 PM | fool.comRock Springs Capital Management LP Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)April 23 at 6:56 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Invesco Ltd.April 23 at 3:41 AM | marketbeat.comScholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...April 22 at 2:47 AM | finance.yahoo.comJump Financial LLC Purchases Shares of 75,108 Scholar Rock Holding Co. (NASDAQ:SRRK)April 20, 2025 | marketbeat.comMarshall Wace LLP Has $127.30 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)April 18, 2025 | marketbeat.comEAM Investors LLC Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)April 18, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Up 5.8% - Here's WhyApril 17, 2025 | marketbeat.comScholar Rock: Apitegromab Approval And Obesity Shot Make For Rating UpgradeApril 17, 2025 | seekingalpha.comAlliancebernstein L.P. Buys 22,480 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)April 16, 2025 | marketbeat.comGeode Capital Management LLC Grows Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)April 14, 2025 | marketbeat.comFmr LLC Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)April 11, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Stock Position Reduced by ExodusPoint Capital Management LPApril 8, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Trexquant Investment LPApril 8, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Receives Average Rating of "Buy" from AnalystsApril 8, 2025 | marketbeat.comWellington Management Group LLP Buys 1,525,845 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)April 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to Come3 Momentum Stocks Near 52-Week Highs to Watch for More GrowthBy Chris Markoch | March 28, 2025View 3 Momentum Stocks Near 52-Week Highs to Watch for More GrowthD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyQualcomm Breaks Down But RSI Signals It’s Severely OversoldBy Sam Quirke | April 8, 2025View Qualcomm Breaks Down But RSI Signals It’s Severely OversoldBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?By Jea Yu | April 4, 2025View Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?QURE, MOR, SRRK, and PTGX Company DescriptionsMorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 04/24/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Protagonist Therapeutics NASDAQ:PTGX$44.49 -0.36 (-0.80%) Closing price 04:00 PM EasternExtended Trading$44.50 +0.02 (+0.03%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.uniQure NASDAQ:QURE$14.18 -0.08 (-0.56%) Closing price 04:00 PM EasternExtended Trading$13.99 -0.19 (-1.34%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Scholar Rock NASDAQ:SRRK$32.81 -1.57 (-4.57%) Closing price 04:00 PM EasternExtended Trading$32.83 +0.02 (+0.05%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
